Literature DB >> 2904886

Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.

K S Chang1, L C Wang, C L Gao, S Alexander, R C Ting, A Bodner, T Log, A F Kuo, P Strickland.   

Abstract

Serum samples collected from four groups of individuals in the Washington, D.C. area were examined for the presence of IgG and IgM classes of antibody reacting against HTLV-I and HIV-1. These four groups were: (1) healthy adults with negative premarital VDRL test for syphilis (n = 113), (2) miscellaneous common disease patients (n = 155), (3) drug abusers (n = 130), and (4) homosexual men (n = 187). The former two groups are considered to be low-risk groups, and the latter two, high-risk groups. The prevalence of IgG antibody on ELISA/Western blot tests for these groups were respectively: (1) 5.3%/1.8%, (2) 5.2%/1.9%, (3) 13.9%/4.6%, and (4) 4.3%/1.6% for HTLV-I, and (1) 2.7%/0.9%, (2) 4.5%/0%, (3) 12.3%/5.4%, and (4) 8.0%/5.9% for HIV-1. Instances of possible concomitant infection as shown by the presence of antibodies against both HTLV-I and HIV-1 were found only in the latter two high-risk groups, i.e. two (1.5%) in group (3), and three (1.6%) in group (4) as confirmed by both Western blot and immunofluorescence tests. Out of 97 sera collected from drug abusers in 1985-86 which had IgG antibody by Western blot test against HIV-1, 23 (23.7%) were HTLV-I antibody positive by ELISA test (Group 5), and 8 of these were confirmed by Western blot test. Among these 8 persons, IgM antibody against HTLV-I was found in 2, while that against HIV-1 was positive in 7 persons.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2904886     DOI: 10.1007/BF00146393

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

2.  Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression.

Authors:  W C Greene; W J Leonard; Y Wano; P B Svetlik; N J Peffer; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Science       Date:  1986-05-16       Impact factor: 47.728

3.  HLA DR4 antibodies cause positive HTLV-III antibody ELISA results.

Authors:  P Kühnl; S Seidl; G Holzberger
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

4.  Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering.

Authors:  M Maruyama; H Shibuya; H Harada; M Hatakeyama; M Seiki; T Fujita; J Inoue; M Yoshida; T Taniguchi
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

5.  Antiviral antibodies in the sera of homosexual men: correlation with their lifestyle and drug usage.

Authors:  L S Nerurkar; R J Biggar; J J Goedert; W Wallen; P Becker; F West; N Tzan; R Traub; Y J Lee; W Botelar
Journal:  J Med Virol       Date:  1987-02       Impact factor: 2.327

6.  ELISA for detection of IgG and IgM antibodies to HSV-1 and HSV-2 in human sera.

Authors:  D Katz; J K Hilliard; R R Mirkovic; R A Word
Journal:  J Virol Methods       Date:  1986-08       Impact factor: 2.014

7.  Low prevalence in the UK of HTLV-I and HTLV-II infection in subjects with AIDS, with extended lymphadenopathy, and at risk of AIDS.

Authors:  R S Tedder; D C Shanson; D J Jeffries; R Cheingsong-Popov; P Clapham; A Dalgleish; K Nagy; R A Weiss
Journal:  Lancet       Date:  1984-07-21       Impact factor: 79.321

8.  Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.

Authors:  S Pahwa; R Pahwa; C Saxinger; R C Gallo; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors.

Authors:  A E Williams; C T Fang; D J Slamon; B J Poiesz; S G Sandler; W F Darr; G Shulman; E I McGowan; D K Douglas; R J Bowman
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

10.  Isolation and characterization of a human T cell leukemia virus type II from a hemophilia-A patient with pancytopenia.

Authors:  V S Kalyanaraman; R Narayanan; P Feorino; R B Ramsey; E L Palmer; T Chorba; S McDougal; J P Getchell; B Holloway; A K Harrison
Journal:  EMBO J       Date:  1985-06       Impact factor: 11.598

View more
  4 in total

1.  Human T cell leukaemia virus type 2 tax protein mediates CC-chemokine expression in peripheral blood mononuclear cells via the nuclear factor kappa B canonical pathway.

Authors:  C S Barrios; L Castillo; H Zhi; C-Z Giam; M A Beilke
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

2.  Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages.

Authors:  B Chesebro; J Nishio; S Perryman; A Cann; W O'Brien; I S Chen; K Wehrly
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

3.  Functional inclusion bodies produced in the yeast Pichia pastoris.

Authors:  Fabián Rueda; Brigitte Gasser; Alejandro Sánchez-Chardi; Mònica Roldán; Sandra Villegas; Verena Puxbaum; Neus Ferrer-Miralles; Ugutz Unzueta; Esther Vázquez; Elena Garcia-Fruitós; Diethard Mattanovich; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2016-10-01       Impact factor: 5.328

Review 4.  HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping Review.

Authors:  Daniel Bradshaw; Graham Philip Taylor
Journal:  Front Med (Lausanne)       Date:  2022-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.